Search

Author/Creator Su, Chinyu

1. 14 POST-HOC ANALYSIS OF TOFACITINIB CROHN'S DISEASE PHASE 2 INDUCTION EFFICACY IN SUBGROUPS WITH BASELINE ENDOSCOPIC OR BIOMARKER EVIDENCE OF INFLAMMATION. (18th January 2018)

Authors:
Sands, Bruce E; Panés, Julian; Higgins, Peter D R; Moscariello, Michele; Chan, Gary; Su, Chinyu; Wang, Wenjin; Maller, Eric
Journal:
Inflammatory bowel diseases
Issue:
Volume 24(2018)Supplement 1
Page Start:
S56
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Issue 11 (6th October 2021)

Authors:
Feagan, Brian G.; Khanna, Reena; Sandborn, William J.; Vermeire, Séverine; Reinisch, Walter; Su, Chinyu; Salese, Leonardo; Fan, Haiyun; Paulissen, Jerome; Woodworth, Deborah A.; Niezychowski, Wojciech; Sands, Bruce E.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 54:Issue 11/12(2021)
Page Start:
1442
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Bridging Efficacy of Tofacitinib Immediate‐Release to Extended‐Release Formulations for Treatment of Ulcerative Colitis: Application of a Model‐Informed Drug Development Approach. Issue 8 (13th May 2022)

Authors:
Mukherjee, Arnab; Tsuchiwata, Shinichi; Chang, Cheng; Nicholas, Timothy; Su, Chinyu; Le, Vu H.; Kushner, Joseph; Kulisek, Nicole
Journal:
Clinical pharmacology in drug development
Issue:
Volume 11:Issue 8(2022)
Page Start:
976
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Issue 2 (29th October 2019)

Authors:
Sands, Bruce E.; Armuzzi, Alessandro; Marshall, John K.; Lindsay, James O.; Sandborn, William J.; Danese, Silvio; Panés, Julián; Bressler, Brian; Colombel, Jean‐Frédéric; Lawendy, Nervin; Maller, Eric; Zhang, Haiying; Chan, Gary; Salese, Leonardo; Tsilkos, Konstantinos; Marren, Amy; Su, Chinyu
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 51:Issue 2(2020)
Page Start:
271
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials. (21st April 2021)

Authors:
Panés, Julian; Vermeire, Séverine; Dubinsky, Marla C; Loftus, Edward V; Lawendy, Nervin; Wang, Wenjin; Salese, Leonardo; Su, Chinyu; Modesto, Irene; Guo, Xiang; Colombel, Jean-Frederic
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15:Number 11(2021)
Page Start:
1852
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Efficacy of Tofacitinib in Patients With Ulcerative Colitis by Prior Tumor Necrosis Factor Inhibitor Treatment Status: Results From OCTAVE Induction and Maintenance Studies: 640. (October 2017)

Authors:
Dubinsky, Marla C.; Peyrin‐Biroulet, Laurent; Melmed, Gil Y.; Hou, Jason K.; Woodworth, Deborah A.; Friedman, Gary S.; Zhang, Haiying; Maller, Eric; Quirk, Daniel; Nduaka, Chudy I.; Su, Chinyu
Journal:
American journal of gastroenterology
Issue:
Volume 112(2017)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies. Issue 1 (27th April 2022)

Authors:
Mukherjee, Arnab; Tsuchiwata, Shinichi; Nicholas, Timothy; Cook, Jack A.; Modesto, Irene; Su, Chinyu; D'Haens, Geert R.; Sandborn, William J.
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 112:Issue 1(2022)
Page Start:
90
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Exposure–response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose‐ranging phase 2 trial. (23rd March 2018)

Authors:
Mukherjee, Arnab; Hazra, Anasuya; Smith, Mike K.; Martin, Steven W.; Mould, Diane R.; Su, Chinyu; Niezychowski, Wojciech
Journal:
British journal of clinical pharmacology
Issue:
Volume 84:Number 6(2018:Dec.)
Page Start:
1136
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Fecal Calprotectin Levels, C‐Reactive Protein Levels, and Partial Mayo Score as Early Predictors of Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Treated With Tofacitinib in a Phase 2 Study: 823. (October 2019)

Authors:
Dubinsky, Marla C.; Hudesman, David P.; Kulisek, Nicole; Salese, Leonardo; Paulissen, Jerome; Su, Chinyu; Magro, Fernando
Journal:
American journal of gastroenterology
Issue:
Volume 114 (2019)ACG Abstracts 1:Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗